JPWO2020065409A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020065409A5 JPWO2020065409A5 JP2021517801A JP2021517801A JPWO2020065409A5 JP WO2020065409 A5 JPWO2020065409 A5 JP WO2020065409A5 JP 2021517801 A JP2021517801 A JP 2021517801A JP 2021517801 A JP2021517801 A JP 2021517801A JP WO2020065409 A5 JPWO2020065409 A5 JP WO2020065409A5
- Authority
- JP
- Japan
- Prior art keywords
- substitution
- seq
- positions
- light chain
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000006467 substitution reaction Methods 0.000 claims 47
- 230000027455 binding Effects 0.000 claims 22
- 102100013137 CD40 Human genes 0.000 claims 21
- 101710040446 CD40 Proteins 0.000 claims 21
- 102000004965 antibodies Human genes 0.000 claims 21
- 108090001123 antibodies Proteins 0.000 claims 21
- 230000035772 mutation Effects 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 206010012601 Diabetes mellitus Diseases 0.000 claims 3
- 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 claims 3
- 108010029697 CD40 Ligand Proteins 0.000 claims 2
- 102100003729 CD40LG Human genes 0.000 claims 2
- 102100015543 FCGR2B Human genes 0.000 claims 2
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 206010028417 Myasthenia gravis Diseases 0.000 claims 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cells Anatomy 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000010874 syndrome Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 claims 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims 1
- 206010004161 Basedow's disease Diseases 0.000 claims 1
- 206010004661 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000000594 Bullous Pemphigoid Diseases 0.000 claims 1
- 206010009839 Coeliac disease Diseases 0.000 claims 1
- 206010011686 Cutaneous vasculitis Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000000999 Encephalomyelitis, Autoimmune, Experimental Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 206010018620 Goodpasture's syndrome Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 201000004779 Graves' disease Diseases 0.000 claims 1
- 208000006454 Hepatitis Diseases 0.000 claims 1
- 201000007313 Kawasaki disease Diseases 0.000 claims 1
- 208000002741 Leukoplakia Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000001725 Mucocutaneous Lymph Node Syndrome Diseases 0.000 claims 1
- 208000004235 Neutropenia Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000005987 Polymyositis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000003782 Raynaud Disease Diseases 0.000 claims 1
- 206010037912 Raynaud's phenomenon Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000006045 Spondylarthropathy Diseases 0.000 claims 1
- 206010052775 Spondyloarthropathy Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 201000000939 bone lymphoma Diseases 0.000 claims 1
- 201000005216 brain cancer Diseases 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 230000001404 mediated Effects 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 201000002728 primary biliary cirrhosis Diseases 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000009594 systemic scleroderma Diseases 0.000 claims 1
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018010828 | 2018-09-28 | ||
| CNPCT/CN2018/010828 | 2018-09-28 | ||
| PCT/IB2019/001135 WO2020065409A2 (en) | 2018-09-28 | 2019-09-27 | Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022503961A JP2022503961A (ja) | 2022-01-12 |
| JPWO2020065409A5 true JPWO2020065409A5 (zh) | 2022-10-04 |
Family
ID=69950020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517801A Pending JP2022503961A (ja) | 2018-09-28 | 2019-09-27 | 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途 |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2022503961A (zh) |
| AU (1) | AU2019349874A1 (zh) |
| CA (1) | CA3114567A1 (zh) |
| WO (1) | WO2020065409A2 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3097007A1 (en) | 2018-04-20 | 2019-10-24 | Lyvgen Biopharma Co., Ltd. | Anti-cd40 antibodies and uses thereof |
| AU2021408091A1 (en) * | 2020-12-23 | 2023-07-13 | Genmab A/S | Modified immunoglobulin with affinity for fcgammariib and method of use thereof |
| WO2024126293A1 (en) * | 2022-12-13 | 2024-06-20 | Evotec International Gmbh | Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection |
| WO2024126289A1 (en) * | 2022-12-13 | 2024-06-20 | Evotec International Gmbh | Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection |
| WO2024126294A1 (en) * | 2022-12-13 | 2024-06-20 | Evotec International Gmbh | Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US20050136055A1 (en) * | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
| KR101223373B1 (ko) * | 2003-12-25 | 2013-01-16 | 교와 핫꼬 기린 가부시키가이샤 | 항 ｃｄ４０ 항체의 변이체 |
| EP2125893A2 (en) * | 2007-01-23 | 2009-12-02 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| RU2745801C2 (ru) * | 2015-05-04 | 2021-04-01 | Аподжиникс Аг | Одноцепочечные белки-агонисты рецептора cd40 |
| EP3313886A1 (en) * | 2015-06-29 | 2018-05-02 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
| CN116063494A (zh) * | 2016-03-04 | 2023-05-05 | 洛克菲勒大学 | 具有增强的激动剂活性的cd40的抗体 |
-
2019
- 2019-09-27 WO PCT/IB2019/001135 patent/WO2020065409A2/en unknown
- 2019-09-27 CA CA3114567A patent/CA3114567A1/en active Pending
- 2019-09-27 JP JP2021517801A patent/JP2022503961A/ja active Pending
- 2019-09-27 AU AU2019349874A patent/AU2019349874A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11492407B2 (en) | Bispecific checkpoint inhibitor antibodies | |
| US20200231707A1 (en) | Readily isolated bispecific antibodies with native immunoglobulin format | |
| AU2010303142B2 (en) | Bispecific death receptor agonistic antibodies | |
| CN107474136B (zh) | 增强激动型抗体活性的抗体重链恒定区序列 | |
| JP2019500892A5 (zh) | ||
| JP2018517401A5 (zh) | ||
| KR20150130349A (ko) | 4가 이중특이적 항체 | |
| JP2013505732A5 (zh) | ||
| US20230052369A1 (en) | Antibody constructs binding 4-1bb and tumor-associated antigens and uses thereof | |
| KR20210134725A (ko) | Enpp3과 cd3에 결합하는 이종이량체 항체 | |
| CA3098096A1 (en) | Antibody against tim-3 and application thereof | |
| JPWO2019198051A5 (zh) | ||
| JPWO2019226973A5 (zh) | ||
| JPWO2020065409A5 (zh) | ||
| KR20220121822A (ko) | FcγRIIB 친화력이 강화된 항체 Fc 영역 | |
| CA3130628A1 (en) | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders | |
| JPWO2021019389A5 (zh) | ||
| IL293640A (en) | CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors | |
| JPWO2021181366A5 (zh) | ||
| RU2021137311A (ru) | ИММУНОЛОГИЧЕСКАЯ ТОЛЕРАНТНОСТЬ К MAdCAM | |
| CN116583300A (zh) | 多特异性抗原结合蛋白 |